参考文献/References:
[1] Xia N,Zhou S,Liang Y,et al. CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves’ ophthalmopathy[J]. Int J Mol Med,2006,17(5):911-916.
[2] Hunt PJ,Marshall SE,Weetman AP,et al. Cytokine gene polymorphisms in autoimmune thyroid disease[J]. J Clin Endocrinol Metab,2000,85(5):1984-1988.
[3] kumar S,Bahn RS,Relative overexpression of macrophage derived cytokines in orbital adipose tissue from patients with graves’ ophthalmopathy[J]. J Clin Endocrinol Metab,2003,88(9):4246-4250.
[4] Inoue A,Koizumi S,Matsuda A,et al. Graves’ hyperthyroidism showing transient hypothyroidism during interferon therapy for chronic hepatitis type C[J]. Endocr J,2005,52(3):293-298.
[5] Vaidya B,Oakes EJ,Imrie H,et al. CTLA4 gene and Graves’ disease:association of Graves’ disease with the CTLA4 exon 1 and intron 1 polymorphisms,but not with the promoter polymorphism[J]. Clin Endocrinol(Oxf),2003,58(6):732-735.
[6] Han R,Smith TJ. Induction by IL-1beta of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts:modulation of gene promoter activity by IL-4 and IFN-gamma[J],J Immunol,2005,174(5):3072-3079.
[7] Sera N,Kawakami A,Nakashima T,et al. Fas/FasL mediated apoptpsis of thyrocytes in Graves’ disease[J]. Clin Exp Immunol,2001,124(2):197-207.
[8] Koumas L,Smith TJ,Feldon S,et al. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes[J],Am J Pathol,2003,163(4):1291-1300.
[9] Hall MC,Yong DA,Waters JG,et al. The comparative role of activator protein 1 and smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1[J]. J Biol Chem,2003,278(12):10304-10313.
[10] Pimentel-Muiños FX,Muñoz-Femández MA,Fresno M. Control of T lymphocyte activation and IL-2 receptor expression by endog-enously secreted lymphokines[J]. J Immunol,1994,152(12):5714-5722.
[11] Cawood T,Moriarty P,O’Shea D.Recent development in thyroid eye disease[J],BMJ,2004,329(7462):385-390.
[12] Brand OJ,Lowet CE,Heward JM,et al. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves’ disease using a multilocus test and tag SNPs[J]. Clin Endocrinol(oxf),2007,66(4):508-512.
[13] Simsek G,Karter Y,Aydin S,et al. Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism; changes as a result of reversal to euthyroidism[J]. Chin J Physiol,2003,46(4):181-186.
[14] Wakelkamp IM,Gerding MN,Van Der Meer JW,et al. Both Th1- and Th2-derived cytokines in serum are elevated in Graves’ ophthalmopathy[J]. Clin Exp Immunol,2000,121(3):453-457.
[15] Wang SH,Bretz JD,Phelps E,et al. A unique combination of inflaramatoy cytokines enhances apoptosis of thyroid follicular cells and transforms nondestructive thyroiditis in experimental autoimmune thyroiditis[J],J Immunol,2002,168(5):2470-2474.
[16] Bartalena L,Brogioni S,Grasso L,et al. Lnterleukiir-6 and the thyroid[J]. Eur J Endocrinol,1995,132(4):386-393.
[17] Campbell IK,Roberts LJ,Wicks IP,et al. Molecular targets in immune mediated disease the case of tumour necrosis factor and rheumatoid arthritis[J]. Immunol Cell Biol,2003,81(5):354-366.
[18] Quadbeck B,Stucke M,Eckstein AK,et al. Dysregulation of TNF/TNFR superfamily members:a systemic link between intra-and extrathyroidal manifestations in Graves’ disease[J]. Scand J Immunol,2006,64(5):523-530.
[19] Poulaki V,Mitsiades GS,McMullan C,et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas[J]. J Clin Endocrinol Metab,2003,88(11):5392-5398.
[20] Senturk T,Kozaci LD,Kok F,et al. Proinflammatory cytokine levels in hyperthyroidism[J]. Clin Invest Med,2003,26(2):58-63.
[21] Díez JJ,Hernanz A,Medina S,et al. Serum concentrations of tumour necrosis factor-alpha (TNF-alpha)and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function[J]. Clin Endocrinol(Oxf),2002,57(4):515-521.
[22] Pichler R,Maschek W,Hatz1-Griesenhofer M,et al. Soluble tumour necrosis factor-alpha receptor I and interleukin-6 as markers of activity in thyrotoxic Graves’ disease[J]. Horm Metab Res,2003,35(7):427-433.
[23] Van den Berghe G. Endocrine evaluation of patients with critical illness[J]. Endocrinol Metab Clin North Am,2003,32(2):385-410.
[24] Mitsiades CS,Poulaki V,Mitsiades N. The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer[J]. J Endocrinol,2003,178(2):205-216.
[25] Mincione G,Esposito DL,Di Marcantonio MC,et al. TGF-beta 1 modulation of IGF-I signaling pathway in rat thyroid epithelial cells[J]. Exp Ceil Res,2003,287(2):411-423.
[26] Geenen V. The thymic insulin-like growth factor axis:involvement in physiology and disease[J]. Horm Metab Res,2003,35(11-12):656-663.
[27] Geenen V,Brilot F. Role of the thymus in the development of tolerance and autoimmunity towards the neuroendocrine system[J]. Ann NY Acad Sci,2003,992:186-195.
[28] Savino W,Postel-Vinay MC,Smaniotto S,et al. The thymus gland:a target organ for growth hormone[J]. Scand J Immunol,2002,55(5):442-452.
相似文献/References:
[1]苏丹,赵水喜.甲状腺相关眼病的放射治疗进展[J].国际放射医学核医学杂志,2014,38(2):126.[doi:10.3760/cma.j.issn.1673-4114.2014.02.012]
Su Dan,Zhao Shuixi.The development of radiotherapy for thyroid associated ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):126.[doi:10.3760/cma.j.issn.1673-4114.2014.02.012]
[2]王芹,杜利清,徐畅,等.白细胞介素21基因联合放射对肺癌细胞生长的协同抑制作用[J].国际放射医学核医学杂志,2014,38(3):161.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
Wang Qin,Du Liqing,Xu Chang,et al.Synergism inhibition effect of adenovirus-mediated IL-21 gene combined with ionizing radiation on the growth of pulmonary carcinoma cells[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):161.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[3]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
[4]薛秀青,苏成海.99Tc-亚甲基二膦酸盐的临床应用研究进展[J].国际放射医学核医学杂志,2010,34(5):285.[doi:10.3760/cma.j.issn.1673-4114.2010.05.008]
XUE Xiu-qing,SU Cheng-hai.Progress of 99Tc-methylenediphosphonate in clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):285.[doi:10.3760/cma.j.issn.1673-4114.2010.05.008]
[5]王任飞,谭建,张桂芝,等.131I治疗对Graves眼病转归的影响[J].国际放射医学核医学杂志,2011,35(4):223.[doi:10.3760/cma.j.issn.1673-4114.2011.04.007]
WANG Ren-fei,TAN Jian,ZHANG Gui-zhi,et al.Effect of 131I therapy on outcomes of Graves’ ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):223.[doi:10.3760/cma.j.issn.1673-4114.2011.04.007]
[6]段炼,陆克义,陈霞,等.131I治疗Graves病对甲状腺相关眼病转归的相关因素分析[J].国际放射医学核医学杂志,2011,35(4):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
DUAN Lian,LU Ke-yi,CHEN Xia,et al.Related factors of thyroid-associated ophthalmopathy in patents with Graves’ disease after 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
[7]杨宝军,李险峰,陆克义,等.99Tcm-二亚乙基三胺五乙酸与99Tcm-奥曲肽眼眶显像在甲状腺相关性眼病中的对比研究[J].国际放射医学核医学杂志,2009,33(1):22.[doi:10.3760/cma.j.issn.1673-4114.2009.01.022]
YANG Bao-jun,LI Xian-feng,LU Ke-yi,et al.A comparative study of 99Tcm-diethylene triaminepentaacetic acid and 99Tcm-octreotide orbital scan in thyroid associated ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):22.[doi:10.3760/cma.j.issn.1673-4114.2009.01.022]
[8]郭树龙,张久君.相对低剂量甲泼尼龙联合99Tc-MDP治疗老年Graves眼病的疗效观察[J].国际放射医学核医学杂志,2009,33(5):287.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.010]
GUO Shu-long,ZHA NG Jiu-jun.Efficacy of combined 99Tc-methylenediphosphonate and lower-dose meth ylprednisolone in the treatment of old patients with moderate-to-severe Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):287.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.010]
[9]刘永哲,金顺子.白细胞介素24的研究进展[J].国际放射医学核医学杂志,2007,31(3):179.
LIU Yong-zhe,JIN Shun-zi.Progress of interleukin-24 study[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):179.
[10]赵炎,王俊起,沈婕.Graves病的131I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析[J].国际放射医学核医学杂志,2017,41(6):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]
Zhao Yan,Wang Junqi,Shen Jie.131I therapy versus antithyroid drugs in Graves’ disease:a meta-analysis of randomized controlled trials[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]